Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ravulizumab - Alexion AstraZeneca Rare Disease

X
Drug Profile

Ravulizumab - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN 1210; ALXN 1810; ravulizumab-cwvz; Ultomiris

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; AstraZeneca
  • Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
  • Registered Neuromyelitis optica
  • Phase III Acute kidney injury; IgA nephropathy; Thrombotic microangiopathies
  • Phase II/III Dermatomyositis
  • Phase II Lupus nephritis
  • Discontinued Acute lung injury; Amyotrophic lateral sclerosis; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 23 May 2024 Alexion terminates a phase II/III trial in Dermatomyositis (Treatment-experienced) in Poland, Spain, USA, United Kingdom, South Korea, Italy, Japan, France, Germany (IV), due to the Sponsor decision (NCT04999020) (EudraCT2021-001200-15)
  • 13 Apr 2024 Updated efficacy data from a phase III CHAMPION MG trial in Myasthenia gravis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024).
  • 29 Mar 2024 Phase-III clinical trials in IgA nephropathy (In adults, In the elderly, Treatment-experienced) in Taiwan, South Korea, Japan (IV) (NCT06291376)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top